MRUS 外匯新聞
Merus Says FDA Grants Breakthrough Therapy Designation For Petosemtamab To Treat Head & Neck Cancer
Oncology company Merus N.V. (MRUS) announced Monday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for petosemtamab for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed following treatment with platinum based chemotherapy and an anti-programmed cell death receptor-1 (PD-1) or anti-programmed death ligand 1 (PD-L1) antibody.
RTTNews
|
189天前
